We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Second primary cutaneous melanoma in patients with advanced melanoma treated with anti‐programmed‐death‐receptor‐1 monoclonal antibodies.
- Authors
Charvet, E.; Kramkimel, N.; Chaplain, L.; Gantzer, A.; Kassem, O.; Longvert, C.; Blom, A.; Dupin, N.; Aractingi, S.; Hamon, M.; Zimmermann, U.; Emile, J.‐F.; Sohier, P.; Sidibé, T.; Saiag, P.; Funck‐Brentano, E.
- Abstract
SPCM specimen analysis by dermato-pathologists revealed four superficial spreading melanomas, including one invasive (Breslow thickness 0-3 mm) and three intraepidermal melanomas, which were subsequently surgically re-excised with lateral safety margins of 5 mm (for intraepidermal melanomas) or 10 mm (invasive melanoma). Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed-death-receptor-1 monoclonal antibodies Dear Editor, Cases of second primary cutaneous melanoma (SPCM), which were mostly BRAF-wildtype, have been reported in patients with BRAF-inhibitor-treated advanced cutaneous melanoma.1 Anti-programmed-death-receptor-1 (anti-PD-1) monoclonal antibodies (mAbs) nivolumab and pembrolizumab have also revolutionized the prognosis of these patients, but 10-15% of them experience grade 3-4 adverse events according to common terminology criteria for adverse events.
- Subjects
MONOCLONAL antibodies; MELANOMA; VITILIGO; DYSPLASTIC nevus syndrome; DRUG side effects
- Publication
British Journal of Dermatology, 2021, Vol 184, Issue 4, p746
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.19629